Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study

Drug Category : Array
Conference Category : Array
Lead Author : Sharman J, et al.
Published Date : 29/05/2020
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2020/05/GENUINE-ASCO-2020_FINAL.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top